Bibliography
- Glenner GG. Amyloid deposits and amyloidosis: the β-fibrilloses. N Engl J Med 1980;302:1283-92
- Bergesio F, Ciciani AM, Manganaro M, et al. Renal involvement in systemic amyloidosis. Nephrol Dial Transplant 2008;23:941-51
- Lachmann HJ, Goodman HJB, Gilbertson JA, et al. Natural history and outcome in systemic AA amyloidosis. N Engl J Med 2007;356:2361-71
- Gertz MA, Kyle RA. Secondary systemic amyloidosis: response and survival in 64 patients. Medicine 1991;70:246-56
- Joss N, McLaughlin K, Boulton-Jones JM. Presentation, survival and prognostic markers in AA amyloidosis. QJM 2000;93(8):535-42
- Zemer D, Pras M, Sohar E, et al. Colchicine in the prevention and the treatment of the amyloidosis of familial Mediterranenan fever. N Engl J Med 1980;314:1001-5
- Urieli-Shoval S, Linke RP, Matzner Y. Expression and function of serum amyloid A, a major acute-phase protein, in normal and disease states. Curr Opin Hematol 2000;7:64-9
- Ledue TB, Weiner DL, Sipe JD, et al. Analytical evaluation of particle enhanced immunonephelometric assays for C-reactive protein, serum amyloid A and mannose-binding protein in human serum. Ann Clin Biochem 1998;35:745-53
- Rocken C, Radum D, Glasbrenner B, et al. Generalized AA-amyloidosis in a 58-year-old Caucasian women with an 18-month history of gastrointestinal tuberculosis. Virchows Arch 1999;434:95-100
- Nakamura T, Baba S, Yamamura Y, et al. Combined treatment with cyclophosphamide and prednisolone is effective for secondary amyloidosis with SAA1γ/γ genotype in a patient with rheumatoid arthritis. Mod Rheumatol 2000;10:160-4
- Kisilevsky R, Lemieux LJ, Fraser PE, et al. Arresting amyloidosis in vivo using small molecule anionic sulphonates or sulphates: implications for Alzheimer's disease. Nat Med 1995;1:143-8
- Goldfinger SE. Colchicine for familial Mediterranean fever. N Engl J Med 1972;287:1302
- Suzuki A, Ohosone Y, Obana M, et al. Cause of death in 81 autopsied patients with rheumatoid arthritis. J Rheumatol 1994;21:33-6
- Ishii W, Matsuda M, Nakamura A, et al. Abdominal fat aspiration biopsy and genotyping of serum amyloid A contribute to early diagnosis of reactive AA amyloidosis secondary to rheumatoid arthritis. Intern Med 2003;42:800-5
- Carmona L, Gonzalez-Alvaro I, Balsa A, et al. Rheumatoid arthritis in Spain: occurrence of extra-articular manifestations and estimates of disease severity. Ann Rheum Dis 2003;62:897-900
- Gillmore JD, Lovat LB, Persey MR, et al. Amyloid load and clinical outcome in AA amyloidosis in relation to circulating concentration of serum amyloid A protein. Lancet 2001;358:24-9
- Remuzzi G, Bertani T. Pathophysiology of progressive nephropathies. N Engl J Med 1998;339:1448-56
- Odabas AR, Cetinkaya R, Selcuk Y, Bilen H. Effect of losartan treatment on the proteinuria in normotensive patients having proteinuria due to secondary amyloidosis. Uppsala J Med Sci 2001;106:183-8
- Cakar N, Yalcinkaya F, Ozkaya N, et al. Familial Mediterranean fever (FMF)-associated amyloidosis in childhood: clinical features, course and outcome. Clin Exp Rheumatol 2001;5(Suppl 24):S63-7
- Ozdemir BH, Ozdemir FN, Sezer S, et al. Does colchicine have an antifibrotic effect on development of interstitial fibrosis in renal allografts of recipients with familial mediterranean fever? Transpl Proc 2006;38:473-6
- Kaaroud H, Boubaker K, Beji S, et al. Renal amyloidosis followed more than 5 years: report of 12 cases. Transpl Proc 2004;36:1796-8
- Ahlmen M, Ahlmen J, Svalander C, Bucht H. Cytotoxic drug treatment of reactive amyloidosis in rheumatoid arthritis with special reference to renal insufficiency. Clin Rheumatol 1987;6:27-38
- Berglund K, Thysell H, Keller C. Results, principles and pitfalls in the management of renal AA-amyloidosis: a 10 – 21 year followup of 16 patients with rheumatic disease treated with alkylating cytostatics. J Rheumatol 1993;20:2051-7
- Chevrel G, Jenvrin C, McGregor B, Miossec P. Renal type AA amyloidosis associated with rheumatoid arthritis: a cohort study showing improved survival on treatment with pulse cyclophosphamide. Rheumatology (Oxford) 2001;40:821-5
- Fiter J, Nolla JM, Valverde J, Roig ED. Methotrexate treatment of amyloidosis secondary to rheumatoid arthritis. Rev Clin Esp 1995;195:390-2
- Nakamura T, Yamamura Y, Tomoda K, et al. Efficacy of cyclophosphamide combined with prednisolone in patients with AA amyloidosis secondary to rheumatoid arthritis. Clin Rheumatol 2003;22:371-5
- Nakamura T, Higashi S, Tomoda K, et al. Significance of SAA1.3 allele genotype in Japanese patients with amyloidosis secondary to rheumatoid arthritis. Rheumatology (Oxford) 2006;45:43-9
- Elkayam O, Hawkins PN, Lachmann H, et al. Rapid and complete resolution of proteinuria due to renal amyloidosis in a patient with rheumatoid arthritis treated with infliximab. Arthritis Rheum 2002;46:2571-3
- Ortiz-Santamaria V, Valls-Roc M, Sanmarti M, Olive A. Anti-TNF treatment in secondary amyloidosis. Rheumatology (Oxford) 2003;42:1425-6
- Gottenberg J-E, Merle-Vincent F, Bentaberry F, et al. Anti-tumor necrosis factor α therapy in fifteen patients with AA amyloidosis secondary to inflammatory arthritides. A follow-up report of tolerability and efficacy. Arthritis Rheum 2003;48:2019-24
- Fernandes-Nebro A, Tomero E, Ortiz-Santamaria V, et al. Treatment of rheumatic inflammatory disease in 25 patients with secondary amyloidosis using tumor necrosis factor alpha antagonists. Am J Med 2005;118:552-6
- Gervais F, Morissette C, Kong X. Proteoglycans and amyloidogenic proteins in peripheral amyloidosis. Curr Med Chem Immun Endocr Metab Agents 2003;3:361-70
- Gervais F, Chalifour R, Garceau D, et al. Glycosaminoglycan mimetics: a therapeutic approach to cerebral amyloid angiopathy. Amyloid 2001;8(Suppl 1):28-35
- Snow AD, Willmer J, Kisilevsky R. Sulfated glycosaminoglycans: a common constituent of all amyloids? Lab Invest 1987;56:120-3
- Lyon AW, Narindrasorasak S, Young ID, et al. Co-deposition of basement membrane components during the induction of murine splenic AA amyloid. Lab Invest 1991;64:785-90
- Stenstad T, Magnus JH, Husby G. Characterization of proteoglycans associated with mouse splenic AA amyloidosis. Biochem J 1994;303:663-70
- Kisilevsky R. The relation of proteoglycans, serum amyloid P and apo E to amyloidosis current status, 2000. Amyloid 2000;7:23-5
- Garceau D, Gurbindo C, Laurin J. Safety, tolerability and pharmacokinetic profile of Fibrillex™ (anti-AA amyloid agent) in healthy and renal impaired subjects. In: Bély M, Apathy A, editors, Proc IXth Int Symp Amyloidosis. David Apathy, Budapest; 2001; p. 116-8
- Dember LM, Hawkins PN, Hanzenberg BPC, et al. Eprodisate for the treatment of renal disease in AA amyloidosis. N Engl J Med 2007;356:2349-60
- Revill P, Serradell N, Bolos J. Drugs Future 2006;31:576-8
- Neurochem withdraws its marketing authorisation application for Kiacta (eprodisate disodium). Doc. Ref. EMEA/137989/2008. Available from: http://www.emea.europa.eu/humandocs/PDFs/EPAR/kiacta/13798908en.pdf [Accessed 26 June 2008]